|
US723288A
(en)
|
1901-10-26 |
1903-03-24 |
Harry South Lewis |
Cipher-key for cryptographic codes.
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
|
ATE370961T1
(de)
|
1998-05-06 |
2007-09-15 |
Genentech Inc |
Reinigung von antikörpern durch ionenaustauschchromatographie
|
|
MXPA01011502A
(es)
*
|
1999-05-14 |
2003-08-20 |
Boehringer Ingelheim Pharma |
Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas.
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
AU5345901A
(en)
|
2000-04-13 |
2001-10-30 |
Univ Rockefeller |
Enhancement of antibody-mediated immune responses
|
|
EP1238678A1
(en)
|
2001-03-08 |
2002-09-11 |
Bayer Aktiengesellschaft |
Enzyme-activated cytostatic conjugates with integrin ligands
|
|
CA2478047C
(en)
|
2002-03-01 |
2014-01-21 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
WO2005086875A2
(en)
|
2004-03-11 |
2005-09-22 |
City Of Hope |
A humanized anti-cea t84.66 antibody and uses thereof
|
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
US20070014795A1
(en)
|
2004-12-30 |
2007-01-18 |
Dhodapkar Madhav V |
Compositions and methods for enhanced dendritic cell maturation and function
|
|
AU2006312148B2
(en)
|
2005-11-07 |
2012-04-12 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
|
NZ569204A
(en)
|
2005-12-21 |
2012-03-30 |
Micromet Ag |
Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
|
|
US20080131428A1
(en)
|
2006-02-24 |
2008-06-05 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
US7420040B2
(en)
|
2006-02-24 |
2008-09-02 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
PE20090245A1
(es)
|
2007-05-08 |
2009-03-17 |
Genentech Inc |
Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
|
|
BRPI0818780A2
(pt)
|
2007-10-19 |
2015-04-22 |
Genentech Inc |
Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
|
|
PL3912643T3
(pl)
|
2009-02-13 |
2023-01-23 |
Immunomedics Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
|
IN2012DN03354A
(enExample)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
|
JP5845899B2
(ja)
|
2010-02-04 |
2016-01-20 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
EA201500220A1
(ru)
|
2010-05-17 |
2015-10-30 |
Ливтех, Инк. |
Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
|
|
WO2011155579A1
(ja)
|
2010-06-10 |
2011-12-15 |
北海道公立大学法人札幌医科大学 |
抗Ｔｒｏｐ－２抗体
|
|
EP2640727B1
(en)
|
2010-11-17 |
2015-05-13 |
Genentech, Inc. |
Alaninyl maytansinol antibody conjugates
|
|
KR101981342B1
(ko)
|
2011-03-02 |
2019-05-22 |
로슈 글리카트 아게 |
Cea 항체
|
|
KR101968499B1
(ko)
|
2011-08-04 |
2019-04-12 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
|
MX348579B
(es)
|
2011-08-04 |
2017-06-20 |
Toray Industries |
Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
|
|
ES2672695T3
(es)
|
2011-08-04 |
2018-06-15 |
Toray Industries, Inc. |
Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
|
|
CN103764825B
(zh)
|
2011-08-04 |
2015-09-02 |
东丽株式会社 |
癌的治疗和/或预防用药物组合物
|
|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
|
US9427464B2
(en)
|
2011-11-22 |
2016-08-30 |
Chiome Bioscience Inc. |
Anti-human TROP-2 antibody having an antitumor activity in vivo
|
|
IN2014KN01714A
(enExample)
|
2012-02-21 |
2015-10-23 |
Toray Industries |
|
|
AU2013223143B2
(en)
|
2012-02-21 |
2017-12-21 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
|
MX357505B
(es)
|
2012-02-21 |
2018-07-12 |
Toray Industries |
Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
|
|
ES2739380T3
(es)
|
2012-02-21 |
2020-01-30 |
Toray Industries |
Composición farmacéutica para el tratamiento del cáncer
|
|
WO2014014082A1
(ja)
|
2012-07-19 |
2014-01-23 |
東レ株式会社 |
癌の検出方法
|
|
CA2879185C
(en)
|
2012-07-19 |
2021-08-24 |
Toray Industries, Inc. |
Method for detecting cancer
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
PT3199552T
(pt)
|
2012-11-20 |
2020-03-25 |
Sanofi Sa |
Anticorpos anti-ceacam5 e suas utilizações
|
|
CA2918989C
(en)
|
2013-08-09 |
2021-11-02 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
|
SG10201902571VA
(en)
|
2013-12-25 |
2019-04-29 |
Daiichi Sankyo Co Ltd |
Anti-trop2 antibody-drug conjugate
|
|
HRP20210977T1
(hr)
|
2014-02-10 |
2021-09-17 |
Merck Patent Gmbh |
Ciljano inhibiranje tgf beta
|
|
US9884876B2
(en)
|
2014-05-09 |
2018-02-06 |
Kineta, Inc. |
Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
|
|
JP6805142B2
(ja)
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ７３に対する抗体およびその使用
|
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
US20190008918A1
(en)
|
2016-03-08 |
2019-01-10 |
Bioxcel Corporation |
Immunomodulation therapies for cancer
|
|
WO2018079740A1
(ja)
|
2016-10-28 |
2018-05-03 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
CA3078309A1
(en)
*
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Methods for administering sting agonists
|
|
WO2019084060A1
(en)
*
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
US10793557B2
(en)
|
2018-04-03 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
Sting agonist compounds
|
|
US20210154316A1
(en)
*
|
2018-05-17 |
2021-05-27 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
|
EP3906055A4
(en)
|
2019-01-04 |
2023-01-04 |
Trio Pharmaceuticals, Inc. |
MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
|
|
JP2022537158A
(ja)
*
|
2019-06-13 |
2022-08-24 |
ボルト バイオセラピューティクス、インコーポレーテッド |
アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
|
|
US20220313835A1
(en)
*
|
2019-09-03 |
2022-10-06 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
EP4038053A1
(en)
*
|
2019-09-30 |
2022-08-10 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
EP4048315B1
(en)
*
|
2019-10-25 |
2025-03-12 |
Bolt Biotherapeutics, Inc. |
Thienoazepine immunoconjugates, and uses thereof
|